LBL-054 TDC / Leads Biolabs - LARVOL DELTA

LBL-054 TDC: A first-in-class CDH17 targeted T cell engager drug conjugate for the treatment of CDH17-positive gastrointestinal cancer (AACR 2026) - "Our results demonstrate that LBL-054 TDC combines the potent, direct killing of an ADC with the T-cell redirecting activity of a TCE both in vitro and in vivo while posing a lower cytokine release than a conventional TCE. It also exhibited good safety profiles in cynomolgus monkeys. Overall, LBL-054 TDC holds promise for treating gastrointestinal cancers with varying T-cell infiltration and CDH17 expression, potentially benefiting a broad patient population."

Gastrointestinal Cancer • Oncology • Solid Tumor • CDH17